Clinical trials: Anticoagulant Therapy
Atrial Fibrillation, Thrombus Due to Heart Valve Prosthesis
The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT
Warfarin is an anticoagulant medication that is highly effective at preventing clotting disorders but which has a narrow therapeutic window.
- Conditions
- Atrial Fibrillation, Thrombus Due to Heart Valve Prosthesis, Deep Venous Thrombosis, Thromboembolism
- Trial name
- NCT02376803
- Testing
- Warfarin
- Where
- 2 sites in Canada
- Volunteers
- 217 people
- Sponsor
- University of Alberta
Acute Myocardial Infarction, Unstable Angina
PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy
Approximately 5 to 8% of patients undergoing percutaneous coronary interventions requires chronic anticoagulant therapy due to atrial fibrillation or other clinical entities.
- Conditions
- Acute Myocardial Infarction, Unstable Angina, Chronic Stable Angina
- Trial name
- PERSEO (NCT03392948)
- Where
- 10 sites in Italy
- Volunteers
- 1,080 people
- Sponsor
- Italian Society of Invasive Cardiology
Acute Kidney Injury
Investigating Different Anticoagulants for Renal Replacement Therapy
The aim of this study is to evaluate the effect of regional citrate anticoagulation within the scope of continuous renal replacement (CRRT) in critically ill patients with acute kidney injury (AKI) on filter life span and 90-day…
- Trial name
- RICH (NCT02669589)
- Testing
- Heparin, Citrate
- Where
- 31 sites in Germany
- Volunteers
- 638 people
- Sponsor
- University Hospital Muenster
Heparin-Induced Thrombocytopenia, Thrombosis
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome…
- Trial name
- NCT00043940
- Testing
- bivalirudin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Medicines Company
Cirrhosis, HCC - Hepatocellular Carcinoma
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
- Conditions
- Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- NCT07132515
- Testing
- Enoxaparin, warfarrin, or apixaban
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Atrial Fibrillation
Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation
To determine whether a comprehensive evaluation and customized multilevel educational interventions will increase the rate of use of oral anticoagulants and the adherence and persistence of use in patients with atrial…
- Trial name
- IMPACT-AF (NCT02082548)
- Testing
- Educational Intervention
- Where
- 5 sites in Argentina, Brazil and 3 more
- Volunteers
- 2,374 people
- Sponsor
- Duke University
Anticoagulants and Bleeding Disorders
MAC Project, Monitoring of AntiCoagulant Therapies (MAC)
MAC Project is a prospective cohort, multicenter, observational, no-profit study aimed to prospectively collect reliable real-life clinical information in unselected VTE or NVAF patients treated with any DOAC, during a…
- Trial name
- MAC (NCT04329390)
- Testing
- Anticoagulant drugs
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Quovadis Associazione
Cancer, Venous Thromboembolism
Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study
Objective: To prospectively evaluate clinical outcomes during guideline-recommended LMWH dose escalation for recurrent VTE during LMWH or DOAC treatment for cancer-associated thrombosis.
- Conditions
- Cancer, Venous Thromboembolism, Recurrence
- Trial name
- REDUCE (NCT05229471)
- Where
- 9 sites in Italy, Netherlands and 1 more
- Volunteers
- 220 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Venous Thromboembolism
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia…
- Trial name
- NCT06714734
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Atrial Fibrillation
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
Study types and hypotheses: multicenter randomized controlled trials. This study predicts that standardized anticoagulation management of atrial fibrillation in primary health care institutions can reduce the prevalence of atrial…
- Trial name
- AMS-AF (NCT05316870)
- Testing
- Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions, Conventional general practitioner management model
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Beijing Municipal Health Commission
Anticoagulants and Bleeding Disorders, Tissue Adhesion
Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
This study aimed to clarify the safety of anticoagulant therapy after glue injection for cirrhotic variceal bleeding patients with portal vein thrombosis.
- Conditions
- Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding
- Trial name
- NCT05545475
- Testing
- Low molecular weight heparin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Deep Vein Thrombosis
Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots
Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disorder after myocardial infarction and stroke.
- Trial name
- STEP-CAT (NCT02752607)
- Where
- 7 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Dr. Vicky Tagalakis
Intracerebral Hemorrhage
Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors apixaban and rivaroxaban.
- Trial name
- TICH-NOAC (NCT02866838)
- Testing
- Tranexamic acid, Saline 0.9%
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- University Hospital, Basel, Switzerland
Influenza
Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation Therapy
Until now, the best administration route of the anti-flu vaccine for patients receiving long term oral anticoagulation therapy has been the subcutaneous one; the intramuscular route has not been recommended because it may…
- Trial name
- NCT00137579
- Testing
- Influenza vaccine intramuscular administration route
- Where
- 4 sites in Spain
- Volunteers
- 216 people
- Sponsor
- Catalan Institute of Health
Venous Thromboembolism, Neoplasms
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Background Patients with cancer and a first deep venous thrombosis of the leg or pulmonary embolism (venous thromboembolism, VTE) are generally treated with low molecular weight heparin (LMWH)injections for 6 months, since this…
- Trial name
- Longheva (NCT01164046)
- Testing
- low molecular weight heparin, vitamin K antagonists
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 56 people
- Sponsor
- University Medical Center Groningen
Subject Under Anticoagulant
Prospective Real-world Registry Describing Treatment Regimens
This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
- Trial name
- PRAETORIAN (NCT03942913)
- Testing
- an observational study
- Where
- France
- Volunteers
- 573 people
- Sponsor
- Assistance Publique Hopitaux De Marseille